Comparison of the Efficacy of Topical Luliconazole 2% Cream vs Topical Ketoconazole 1% Cream in the Treatment of Pityriasis Versicolor.

Trial statusNot yet recruiting
Trial phasePhase 4
Trial typeInterventional
Biological sexAll
Age18-50
SponsorPAEC General Hospital, Islamabad

About this trial

Pityriasis versicolor is a common superficial fungal infection caused by Malassezia species, characterized by hypo- or hyper-pigmented scaly patches on the skin. Topical antifungal agents are the mainstay of treatment. Ketoconazole has been widely used; however, newer agents such as luliconazole may offer improved efficacy and shorter treatment duration. This randomized controlled study aims to compare the efficacy and safety of topical luliconazole versus topical ketoconazole in patients with pityriasis versicolor. Treatment response will be assessed clinically and mycologically to determine comparative outcomes.

Eligibility criteria

Qualifiers

All patients diagnosed with pityriasis versicolor.

Disqualifiers

Immunocompromised patients

Trial design

Treatments tested in this trial

  • Luliconazole Cream 1%
  • Topical ketoconazole 2% cream

Treatment groups

86 Participants
are divided into 2 treatment groups

Locations

This trial has no locations

Sponsors and collaborators

PAEC General Hospital, Islamabad

Lead sponsor

PAEC general hospital

Collaborator